Ireland has launched a five-year strategy to boost research and innovation. It sets out how the newly minted funder Research ...
Zymeworks Inc. is rated a Buy with improved FY25 profitability, narrowed net loss by 34%, and strong liquidity with $270.6M.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results